PTSD Research Pipeline

According to NIH funding data, public investment in PTSD research in the United States is at a very large level, and that investment has been rising year on year. This suggests that PTSD is treated as a serious research priority by major government health funders. For patients, a growing funding base generally means more studies are being supported, which can translate into a broader pipeline of potential treatments being explored over time.

Registry data shows that clinical trials for PTSD are active at both early and late stages, meaning research is not just at the exploratory beginning but has also progressed through to more advanced testing in some areas. Early stage trials, such as Phase 1 and Phase 2 studies, explore safety and initial effectiveness, while late stage trials such as Phase 3 studies test treatments in larger groups of people. The presence of activity across both ends of the pipeline suggests that some approaches are maturing, even if no treatment has yet completed the full journey to approval.

For Australian patients, it is important to understand that no TGA approval has been recorded for the treatments currently moving through this pipeline, and no PBS listing has been recorded either. This means that, based on currently tracked data, these investigational treatments are not yet available as standard, subsidised options in Australia. Patent activity has also not been recorded, which may affect how quickly treatments could eventually be manufactured and made widely available. Patients who are interested in participating in research should speak with their treating doctor about whether any trials are accessible to them locally.

This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.